SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.

Slides:

Advertisements

Similar presentations

1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.

Advertisements

McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.

K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

CHARM Program: 3 Component trials comparing candesartan with placebo.

Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

analysis from the SHIFT study

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda on behalf of the Investigators.

ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.

CIBIS III Ronnie Willenheimer University Hospital, Malmö, Sweden, on behalf of the CIBIS III investigators Results of the randomized Cardiac Insufficiency.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Objective, design and baseline Swedberg.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Update on Valsartan Špinar J.. System renin-angiotensin-aldosteron angiotensinogen angiotensin I angiotensin II aldosteron ANP,BNP thirst resorp. Na +

On behalf of the CHARM Programme Investigators and Committees Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity CHARM.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

A step further in the management of stable coronary patients with ivabradine.

Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

COMET - Background, Rationale and Design Pharmacological Differences Within the  Blocker Class Agents currently evaluated for heart failure 

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.

Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy

CS-1 Safety of Candesartan in CHF When Added to Evidence-based Doses of ACE Inhibitors James W. Hainer, MD, MPH AstraZeneca C.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

CIBIS II Cardiac Insufficiency Bisoprolol Study

S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda and Karl Swedberg on behalf of the Investigators.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

CI-1 ATACAND ® (candesartan cilexetil) Cardiovascular and Renal Drugs Advisory Committee Rockville, Maryland February 24, 2005 C.

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

4S: Scandinavian Simvastatin Survival Study

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Tailoring Intervention – Effectively Targeting the High-risk Population Cardiovascular Event Reduction in the Higher-Risk Primary Prevention Population.

OVERTURE FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Milton Packer, M.D., FACC Columbia University College of Physicians.

Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.

Interim Chair, Medicine Brigham and Women’s Hospital Boston, MA

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

The following slides highlight a report on presentations at a Hotline Session and a Satellite Symposium of the European Society of Cardiology 2003 Congress.

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.

Presenter Disclosure Information

Presentation transcript:

SS-1 Candesartan Support Slides

SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo Metoprolol50%89 mg84 mg Carvedilol31%29 mg28 mg Atenolol8%44 mg47 mg Bisoprolol5%6 mg5 mg Other6%–– 65

SS-3 37 Patients, n (%) Val-HeFT n = 5010 CHARM Added n = 2548 All patients Deaths979 (19.5)789 (26.2) CV deaths846 (16.9)649 (25.5) Patients on ACEi and β-blockern = 1610n = 1413 Deaths226 (14.0)370 (26.2) CV deaths201 (12.5)307 (21.7) Death and CV Death in Patients on ACEi and β-blocker CHARM Added Compared to Val-HeFT CHARM FDA questions.ppt

SS-4 Discontinuation † by Baseline Estimated GFR CHARM Added AZ BD T 40 P 75 Placebo n = 464 Candesartan n = 465 eGFR, mL/min/1.73 m 2 < < 90≥ 90< < 90≥ 90 Patients in each stratified group, n Discontinuation in each stratified group, n (%) 46 (30.1)33 (16.3)13 (12.0)63 (41.2)60 (29.1)12 (11.3) † Calculated by Modification of Diet in Renal Disease formula. North American sites.

SS-5 Outcomes in Patients Discontinued for Renal Dysfunction CHARM Added 62 Outcome_data.ppt Patients, n/N (%) Alive at end of studyPlaceboCandesartan Renal dysfunction20/53 (38)58/105 (55)

SS-6 Estimated GFR † Over Study Time CHARM Added BaselineWk 6Mo 14Mo 38LOCF 59 SAS pgm: box_wisher_gfr_ BaselineWk 6Mo 14Mo 38LOCF PlaceboCandesartan n = n = LOCF = Last observation carried forward. † Calculated by Modification of Diet and Renal Disease formula. North American sites. eGFR, ml/min/1.73 m 2 95% 75% 25% 5% Median

SS-7 CV Mortality or CHF Hospitalization Subgroup Analysis CHARM Added Patients, n/N PlaceboCandesartan Age< 65211/636192/632 ≥ 65 < 75193/391176/432 ≥ 75134/245115/212 GenderMale427/ /1006 Female111/27296/270 NYHAII104/30293/312 III / IV434/970390/964 LVEF< 25203/382186/388 ≥ 25335/890297/888 Medical history DiabetesNo334/890291/900 Yes204/382192/376 HypertensionNo261/653248/667 Yes277/619235/609 Previous MINo224/569188/562 Yes314/703295/714 Atrial fibrillationNo375/931335/929 Yes163/341148/346 DiureticNo27/12626/128 Yes511/ /1148 DigitalisNo185/519172/541 Yes353/753311/735 AspirinNo264/613240/624 Yes274/659243/652 Lipid loweringNo336/751294/748 Yes202/521189/528 USNo410/970355/981 Yes128/302128/295 All patients (N = 2548)538/ /1276 DV CSR SH-AHS-0006 T 101, Placebo betterCandesartan better Hazard ratio (95% CI) Interaction p value 0.115

CV Death or CHF Hospitalization by Country CHARM Added Patients, n Sweden64 Norway97 Denmark207 Finland14 Iceland21 Italy14 Spain17 Portugal19 The Netherlands128 France70 Czech Republic71 Poland79 Hungary69 Switzerland25 Belgium/Luxembourg82 Malaysia38 Singapore21 United Kingdom89 Germany346 Canada357 US597 Australia76 South Africa32 Russia15 All patients2548 Hazard ratio (95% CI) > > > > > US-8 Interaction p value 0.557

SS-9 Patients, n/N p value for interaction PlaceboCandesartan CHARM Added US128/302128/ Non-US410/970355/981 All patients538/ /1276 CHARM Alternative US99/23882/ Non-US307/777252/781 All patients406/ /1013 CHARM Preserved US105/36195/ Non-US261/ /1141 All patients366/ / Low LVEF trials pooled US227/540210/ Non-US717/ /1762 All patients944/ /2289 CHARM—3 trials pooled US332/901305/ Non-US978/ /2903 All patients1310/ /3803 US vs Non-US Patients CV Death or CHF Hospitalization CHARM Program Candesartan better Placebo better SH-AHS-0006 T101, 102, , 2, 3; SH-AHS-0003 T106, 107, , 2, 3; SH-AHS-0003, , 87, , 5, 6; SH-AHS-pooled T ; , , , DV Hazard ratio (95% CI)

SS-10 CV Death or CHF Hospitalization by US and Non-US Patients CHARM Program Patients, n/N p value for interaction PlaceboCandesartan CHARM Added US128/302128/ Non-US410/970355/981 All patients538/ /1276 CHARM Alternative US99/23882/ Non-US307/777252/781 All patients406/ / Low LVEF trials pooled US227/540210/ Non-US717/ /1762 All patients944/ /2289 CHARM Overall—3 trials pooled US332/901305/ Non-US978/ /2903 All patients1310/ /3803 Candesartan better Placebo better Hazard ratio (95% CI) DV

SS-11 Baseline Medications CHARM Added Patients, % US n = 597 Non-US n = 1951 Baseline therapy, % ACE inhibitor100 Recommended dose β-blocker Diuretic Spironolactone Digitalis Aspirin Lipid-lowering CSR SH-AHS-0006 T 20;

SS-12 Baseline Medical History CHARM Added US n = 597 Non-US n = 1951 Medical history, % Myocardial infarction Diabetes Hypertension Atrial fibrillation Coronary artery bypass graft PCI ICD Pacemaker CSR SH-AHS-pooled T 81, S1; CSR SH-AHS-0007 T 80, S1; CSR SH-AHS-0003 T 85, S1; CSR SH-AHS-0006 T 80, S1

SS-13 Most Common † Adverse Events Leading to Treatment Discontinuation CHARM Added Patients, n (%) North AmericaRest of world Placebo n = 477 Candesartan n = 477 Placebo n = 795 Candesartan n = 799 Abnormal renal function ‡ 30 (6.3)46 (9.6)23 (2.9)59 (7.4) Cardiac failure32 (6.7)28 (5.9)49 (6.2)41 (5.1) Hypotension17 (3.6)28 (5.9)27 (3.4)41 (5.1) Hyperkalemia 8 (1.7)21 (4.4) 3 (0.4)28 (3.5) Acute renal failure 8 (1.7) 5 (1.0) 6 (0.8)10 (1.3) † Five leading reasons. ‡ Renal function abnormal/aggravated.

SS-14 Patients, n/N CHARMPlaceboCandesartan AlternativeNon-black387/970328/985 Black19/456/28 AddedNon-black509/ /1211 Black29/6224/65 PreservedNon-black355/ /1445 Black11/5716/69 3 PooledNon-black1251/ /3641 Black59/16446/162 All patients1310/ /3803 CV Death or CHF Hospitalization by Black and Non-Black Patients CHARM Overall Candesartan better Placebo better Hazard ratio (95% CI)

SS-15 Time to First All-Cause Hospitalization 1 mo6 mo12 mo Candesartan Placebo

SS-16 At risk, n Placebo Candesartan Primary Outcome CV Death or CHF Hospitalization CHARM Added 123 Time, yr Placebo Candesartan % 3.5 HR 0.85 (95% CI: 0.75, 0.96), p = Adjusted HR = 0.85, p = (37.9%) 538 (42.3%) 15% risk reduction 0 NNT = 23

SS-17 Investigator-Reported HF Hospitalizations for the Individual CHARM Trials and Overall Program AlternativeAddedPreserved3 pooled Total hospitalizations for CHF Placebo Candesartan p < † p = † p = † p < † † Wilcoxon Rank Sum Test based on number of hospitalizations/follow up time.

SS-18 Total Number of Hospitalizations CHARM Overall—3 Trials Pooled and CHARM Added CHARM OverallCHARM Added Total number of hospitalizations Placebo Candesartan

SS-19 Doses of Most Common ACE Inhibitors at Selected Study Visits CHARM Added Mean ACEi dose, mg/d Patients at baseline, % 1 Baseline 4 6 wk 5 6 mo 7 14 mo mo mo 19 Closing visit Enalapril26.7P C Lisinopril19.1P C Captopril16.8P C Ramipril11.0P C Attachment A, 28 Jan Addendum to Jan Briefing Doc

SS-20 BD Table 48—Summary Table of Concomitant ACE Inhibitor Use (CHARM-Added)

SS-21 Patients, n CV death or CHF hospitalization Recommended dose of ACEiNo1012 Yes1535 Maximum dose of ACEiNo1788 Yes759 All-cause mortality or CHF hospitalization Recommended dose of ACEiNo1012 Yes1535 Maximum dose of ACEiNo1788 Yes759 CV death or CHF hospitalization or nonfatal MI Recommended dose of ACEiNo1012 Yes1535 Maximum dose of ACEiNo1788 Yes759 All-cause mortality Recommended dose of ACEiNo1012 Yes1535 Maximum dose of ACEiNo1788 Yes759 Endpoint Analyses Based on Recommended or Maximum † ACEi Doses During Study CHARM Added 36 Peter Johanson ACE analyses to US T 11 – T 20 Candesartan betterPlacebo better † FDA communication Hazard ratio (95% CI)

SS-22 Doses of Most Common ACEi at Selected Study Visits CHARM Added Enalapril (27%) Captopril (17%) Lisinopril (19%) Ramipril (11%) Baseline Closing Baseline Closing Baseline Closing Baseline Closing 6 wk6 mo14 mo26 mo38 mo6 wk6 mo14 mo26 mo38 mo